Biorestorative Therapies, Inc.

BRTX Healthcare Biotechnology

Biorestorative Therapies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $359,700.00, down 10.3% from fiscal 2024. In the quarter to March 2026, revenue fell 7.20%, EPS grew 81.3% and free cash flow fell 35.3%, each against the same quarter a year earlier.

1.54 0.08 +5.48%
Market cap
$2.0M
P/E
0.0×
Fwd P/E
−0.8×
Dividend yield
—
F-score
4/9
Altman Z
−70.97
Beneish M
−7.56
Dividend safety
n/a
Mar '26 Dec '25 Sep '25 Jun '25 Older periods
Piotroski F-Score
3 4 3 3

+8 more TTM periods

ROE
(241.50%) (321.48%) (208.21%) (137.34%)
ROA
(147.75%) (174.11%) (125.35%) (87.06%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(439.82%) 6,268.49% (801.27%) (251.36%)
Average Days of Receivables
13.56 15.73 12.76 9.05
Free Cash Flow per Share
(13.33) (24.25) (23.63) (22.03)
Free Cash Flow
(11.82) (10.91) (10.77) (9.63)
Other line items

Show all line items

Columns are period end dates